In vitro evaluation of TLR4 agonist activity: Formulation effects

Colloids and Surfaces B: Biointerfaces

Volumn 113, Issue , 2014, Pages 312-319

  Misquith, Ayesha ^a   Fung, H W Millie ^a   Dowling, Quinton M ^a   Guderian, Jeffrey A ^a   Vedvick, Thomas S ^a   Fox, Christopher B ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

Glucopyranosyl lipid adjuvant; In vitro bioactivity; Particle size; Physicochemical characterization; TLR4 agonist; Vaccine adjuvant formulation

Indexed keywords

BIOACTIVITY; EMULSIONS; PARTICLE SIZE; VACCINES;

GLUCOPYRANOSYL LIPID ADJUVANT; IN-VITRO BIOACTIVITY; PHYSICO-CHEMICAL CHARACTERIZATION; TLR4 AGONIST; VACCINE ADJUVANTS;

ASSAYS;

ALUMINUM POTASSIUM SULFATE; GLUCOPYRANOSYL LIPID ADJUVANT; LIPOSOME; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; WATER OIL CREAM;

ARTICLE; BIOASSAY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG FORMULATION; DRUG POTENCY; DRUG SCREENING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIMULUS AMEBOCYTE LYSATE ASSAY; NANOPHARMACEUTICS; PARTICLE SIZE; PRIORITY JOURNAL; SUSPENSION;

LIMULUS;

GLUCOPYRANOSYL LIPID ADJUVANT; IN VITRO BIOACTIVITY; PARTICLE SIZE; PHYSICOCHEMICAL CHARACTERIZATION; TLR4 AGONIST; VACCINE ADJUVANT FORMULATION;

ADJUVANTS, IMMUNOLOGIC; PARTICLE SIZE; TOLL-LIKE RECEPTOR 4;

EID: 84885224335     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2013.09.006     Document Type: Article

References (33)

1. Silliman C.C., Wang M. The merits of in vitro versus in vivo modeling in investigation of the immune system. Environ. Toxicol. Pharmacol. 2006, 21:123-134.
2. Coler R.N., Bertholet S., Moutaftsi M., Guderian J.A., Plessner Windish H., Baldwin S.L., Laughlin E.M., Duthie M.S., Fox C.B., Carter D., Friede M., Vedvick T.S., Reed S.G. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 2011, 6:e16333.
3. Russell W.M.S., Burch R.L. The Principles of Humane Experimental Technique 1959, Methuen, London.
4. Anderson R.C., Fox C.B., Dutill T.S., Shaverdian N., Evers T.L., Poshusta G.R., Chesko J., Coler R.N., Friede M., Reed S.G., Vedvick T.S. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf., B 2010, 75:123-132.
5. Wiley S.R., Raman V.S., Desbien A., BAilor H.R., Bhardway R., Shakri A.R., Reed S.G., Chitnis C.E., Carter D. Targeting TLRs expands the antibody repetoire in response to a malaria vaccine. Sci. Transl. Med. 2011, 3:93ra69.
6. Fox C.B., Baldwin S.L., Vedvick T.S., Angov E., Reed S.G. Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines. Clin. Vaccine Immunol. 2012, 19:1633-1640.
7. Lousada-Dietrich S., Jogdand P.S., Jepsen S., Pinto V.V., Ditley S.B., Christiansen M., Larsen S.O., Fox C.B., Raman V.S., Howard R.F., Vedvick T.S., Ireton G.C., Carter D., Reed S.G., Theisen M. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2-a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine 2011, 29:3284-3292.
8. Pashley R.M., Karaman M.E. Applied Colloid and Surface Chemistry 2004, Wiley, Hoboken, NJ.
9. Fox C.B., Friede M., Reed S.G., Ireton G.C. Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Endotoxins: Structure, Function and Recognition 2010, 303-321. Springer, New York. X. Wang, P.J. Quinn (Eds.).
10. Levin J., Bang F.B. The role of endotoxin in the extracellular coagulation of Limulus blood. Bull. Johns Hopkins Hosp. 1964, 115:265-274.
11. Levin J., Bang F.B. A description of cellular coagulation in the Limulus. Bull. Johns Hopkins Hosp. 1964, 115:337-345.
12. Ziegler-Heitbrock H.W., Thiel E., Futterer A., Herzog V., Wirtz A., Riethmuller G. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int. J. Cancer 1988, 41:456-461.
13. Fox C.B. Characterization of TLR4 agonist effects on Alhydrogel sedimentation: a novel application of laser scattering optical profiling. J. Pharm. Sci. 2012, 101:4357-4364.
14. Filipe V., Hawe A., Jiskoot W. Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm. Res. 2010, 27:796-810.
15. Johnson D.A., Baldridge J.R. TLR4 agonists as vaccine adjuvants. Vaccine Adjuvants and Delivery Systems 2007, John Wiley & Sons, Inc, Hoboken, NJ. M.S. Singh (Ed.).
16. Young N.S., Levin J., Prendergast R.A. An invertebrate coagulation system activated by endotoxin: evidence for enzymatic mechanism. J. Clin. Invest. 1972, 51:1790-1797.
17. Janeway C.A., Travers P., Walport M., Shlomchik M. Immunobiology 5: The Immune System in Health and Disease 2001, Garland Publishing, New York. 5.
18. Siveke J.T., Hamann A. Cutting edge: T helper 1 and T helper 2 cells respond differentially to chemokines. J. Immunol. 1998, 160:550-554.
19. Sakai H., Hisamoto S., Fukutomi I., Keitaro S., Takeoka S., Tsuchida E. Detection of lipopolysaccharide in hemoglobin-vesicles by Limulus amebocyte lysate test with kinetic-turbidimetric gel clotting analysis and pretreatment of surfactant. J. Pharm. Sci. 2004, 93:310-321.
20. Harmon P., Cabral-Lilly D., Reed R.A., Maurio F.P., Franklin J.C., Janoff A. The release and detection of endotoxin from liposomes. Anal. Biochem. 1997, 250:139-146.
21. Zaitseva M., Romantseva T., Blinova K., Beren J., Sirota L., Drane D., Golding H. Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo. Vaccine 2012, 30:4859-4865.
22. Brandenburg K., Seydel U. Conformation and supramolecular structure of lipid A. Adv. Exp. Med. Biol. 2009, 667:25-38.
23. Schromm A.B., Howe J., Ulmer A.J., Wiesmuller K.H., Seyberth T., Jung G., Rossle M., Koch M.H., Gutsmann T., Brandenburg K. Physiochemical and biological analysis of synthetic bacterial lipopeptides: validity of the concept of endotoxic conformation. J. Biol. Chem. 2007, 282:11030-11037.
24. Brandenburg K., Howe J., Gutsman T., Garidel P. The expression of endotoxic activity in the Limulus test as compared to cytokine production in immune cells. Curr. Med. Chem. 2009, 16:2653-2660.
25. McNeil S.E. Challenges for nanoparticle characterization. Methods. Mol. Biol. 2011, 697:9-15.
26. Neun B.W., Dobrovolskaia M.A. Detection and quantitative evaluation of endotoxin contamination in nanoparticle formulations by LAL-based assays. Methods. Mol. Biol. 2011, 697:121-130.
27. Baldwin S.L., Shaverdian N., Goto Y., Duthie M.S., Raman V.S., Evers T., Mompoint F., Vedvick T.S., Bertholet S., Coler R.N., Reed S.G. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009, 27:5956-5963.
28. Orr M.T., Fox C.B., Baldwin S.L., Sivananthan S.J., Lucas E., Lin S., Phan T., Moon J.J., Vedvick T.S., Reed S.G., Coler R.N. Adjuvant formulation structure and composition is critical for the development of an effective vaccine against tuberculosis. J. Controlled Release 2013, 172:190-200.
29. Simberg D., Weisman S., Talmon Y., Barenholz Y. DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Crit. Rev. Ther. Drug Carrier Syst. 2004, 21:257-317.
30. Ma Y., Poisson L., Sanchez-Schmitz G., Pawar S., Qu C., Randolph G.J., Warren W.L., Mishkin E.M., Higbee R.G. Assessing the immunopotency of Toll-like receptor agonists in an in vitro tissue-engineered immunological model. Immunology 2010, 130:374-387.
31. Schneider L.P., Schoonderwoerd A.J., Moutaftsi M., Howard R.F., Reed S.G., de Jong E.C., Teunissen M.B. Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells. Vaccine 2012, 30:4216-4224.
32. Behzad H., Huckriede A.L.W., Haynes L., Gentleman B., Coyle K., Wilschut J.C., Kollmann T.R., Reed S.G., McElhaney J.E. GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J. Infect. Dis. 2012, 205:466-473.
33. Arias M.A., Van Roey G.A., Tregoning J.S., Moutaftsi M., Coler R.N., Windish H.P., Reed S.G., Carter D., Shattock R.J. Glucopyranosyl lipid adjuvant (GLA), a synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS One 2012, 7:e41144.